Exelixis is a biotechnology company that develops innovative cancer treatments, and its portfolio includes CABOMETYX and COMETRIQ products, which work by inhibiting several tyrosine kinases that promote cancer growth. In addition, the company has developed MEK inhibitor COTELLIC and mineralocorticoid receptor blocker MINNEBRO for treating hypertension. Exelixis has research collaborations and license agreements with various biopharmaceutical companies and is headquartered in Alameda, California.